<p>DBV Technologies（纳斯达克代码：DBVT - 获取免费报告）预计将在 2025 年 4 月 10 日星期五市场开盘前发布其 2025 年第四季度财报。分析师预计该公司将宣布每股收益为（$0.1564）和季度收入为 108.90 万美元。投资者可以在公司即将发布的 2025 年第四季度财报页面找到电话会议的详细信息，电话会议定于 2026 年 4 月 2 日星期四上午 7:00（东部时间）。</p>
<p>获取 <strong>DBV Technologies</strong> 警报：</p>
<ul>
<li>3 只逆势而上的生物制药股票</li>
</ul>
<p>DBV Technologies（纳斯达克代码：DBVT - 获取免费报告）最近于 2 月 14 日星期六发布了季度财报。该公司报告季度每股收益（EPS）为（$1.15）。该业务的季度收入为 65 万美元。DBV Technologies 的股本回报率为负的 189.17%，净利润率为负的 2606.83%。分析师平均预计 DBV Technologies 在当前财政年度的每股收益为-$7，在下一个财政年度的每股收益为-$5。</p>
<h2>DBV Technologies 价格表现</h2>
<p>DBV Technologies 的股票在星期五开盘价为$21.06。该股票的市值为 11.7 亿美元，市盈率为-4.03，贝塔值为-0.94。该业务的 50 日简单移动平均为$21.49，200 日简单移动平均为$17.53。DBV Technologies 的 12 个月低点为$6.00，12 个月高点为$26.18。</p>
<h2>对 DBV Technologies 的对冲基金看法</h2>
<p>机构投资者和对冲基金最近买卖了该公司的股票。Ikarian Capital LLC 在第四季度收购了 DBV Technologies 的新股份，价值约为 10,064,000 美元。Vestal Point Capital LP 在第四季度购买了 DBV Technologies 的新头寸，价值约为 5,751,000 美元。Squadron Capital Management LLC 在第四季度收购了 DBV Technologies 的股份，价值约为 4,601,000 美元。Millennium Management LLC 在第四季度将其在 DBV Technologies 的股份增加了 89.7%。Millennium Management LLC 现在拥有 640,885 股该公司的股票，价值为 12,286,000 美元，此前在上个季度又购买了 303,022 股。最后，Engineers Gate Manager LP 在第四季度购买了 DBV Technologies 的新股份，价值约为 479,000 美元。目前 71.74% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师设定新目标价</h2>
<p>一些股票研究分析师最近对该股票发布了报告。Cantor Fitzgerald 在 12 月 17 日星期三的研究报告中将 DBV Technologies 的目标价设定为$48.00。HC Wainwright 在 12 月 18 日星期四的研究报告中将 DBV Technologies 的目标价设定为$40.00。花旗集团在 12 月 17 日星期三的报告中重申了对 DBV Technologies 的 “跑赢大盘” 评级。Weiss Ratings 在 12 月 29 日星期一的研究报告中重申了对 DBV Technologies 的 “卖出（e+）” 评级。最后，Guggenheim 在 3 月 27 日星期五的研究报告中重新发布了 “买入” 评级，并将 DBV Technologies 的目标价设定为$51.00。两位研究分析师对该股票给予了强烈买入评级，四位给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为$38.65。</p>
<p><strong>查看我们关于 DBVT 的最新研究报告</strong></p>
<h2>关于 DBV Technologies</h2>
<p>（获取免费报告）</p>
<p>DBV Technologies SA 是一家临床阶段的生物制药公司，专注于开发过敏性疾病的免疫疗法。该公司专注于皮肤免疫疗法，利用其专有的 Viaskin 平台通过完整的皮肤传递生物活性化合物，无需针头或注射。通过这种方法，DBV 旨在调节患者对特定过敏原的免疫反应，提供一种潜在更安全和更便捷的替代传统疗法的选择。</p>
<p>该公司的主要产品候选药物 Viaskin Peanut 旨在治疗儿童和青少年的花生过敏。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票比 DBV Technologies 更好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REJWVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REJWVA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 DBV Technologies 吗？</h2>
<p>在你考虑 DBV Technologies 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 DBV Technologies 并不在名单上。</p>
<p>虽然 DBV Technologies 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>DBV Technologies（纳斯达克代码：DBVT）将于 4 月 10 日发布 2025 年第四季度财报，分析师预计每股亏损为 0.1564 美元，收入为 108.9 万美元。该公司在上一个季度的财报中报告每股亏损 1.15 美元，收入为 65 万美元。机构投资者持有 71.74% 的股份，分析师的评级意见不一，目标价共识为 38.65 美元。DBV Technologies 专注于开发针对过敏性疾病的免疫疗法，特别是儿童的花生过敏</p>

<p>DBV Technologies (NASDAQ:DBVT - Get Free Report) is projected to post its Q4 2025 results before the market opens on Friday, April 10th. Analysts expect the company to announce earnings of ($0.1564) per share and revenue of $1.0890 million for the quarter. Investors can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, April 2, 2026 at 7:00 AM ET.</p>
<div class="lb-trans"><p>DBV Technologies（纳斯达克代码：DBVT - 获取免费报告）预计将在 2025 年 4 月 10 日星期五市场开盘前发布其 2025 年第四季度财报。分析师预计该公司将宣布每股收益为（$0.1564）和季度收入为 108.90 万美元。投资者可以在公司即将发布的 2025 年第四季度财报页面找到电话会议的详细信息，电话会议定于 2026 年 4 月 2 日星期四上午 7:00（东部时间）。</p>
</div><p>Get <strong>DBV Technologies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>DBV Technologies</strong> 警报：</p>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只逆势而上的生物制药股票</li>
</ul>
</div><p>DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($1.15) earnings per share (EPS) for the quarter. The business had revenue of $0.65 million for the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%. On average, analysts expect DBV Technologies to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>DBV Technologies（纳斯达克代码：DBVT - 获取免费报告）最近于 2 月 14 日星期六发布了季度财报。该公司报告季度每股收益（EPS）为（$1.15）。该业务的季度收入为 65 万美元。DBV Technologies 的股本回报率为负的 189.17%，净利润率为负的 2606.83%。分析师平均预计 DBV Technologies 在当前财政年度的每股收益为-$7，在下一个财政年度的每股收益为-$5。</p>
</div><h2>DBV Technologies Price Performance</h2>
<div class="lb-trans"><h2>DBV Technologies 价格表现</h2>
</div><p>DBV Technologies stock opened at $21.06 on Friday. The stock has a market capitalization of $1.17 billion, a PE ratio of -4.03 and a beta of -0.94. The business has a 50 day simple moving average of $21.49 and a 200-day simple moving average of $17.53. DBV Technologies has a 12 month low of $6.00 and a 12 month high of $26.18.</p>
<div class="lb-trans"><p>DBV Technologies 的股票在星期五开盘价为$21.06。该股票的市值为 11.7 亿美元，市盈率为-4.03，贝塔值为-0.94。该业务的 50 日简单移动平均为$21.49，200 日简单移动平均为$17.53。DBV Technologies 的 12 个月低点为$6.00，12 个月高点为$26.18。</p>
</div><h2>Hedge Funds Weigh In On DBV Technologies</h2>
<div class="lb-trans"><h2>对 DBV Technologies 的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the business. Ikarian Capital LLC acquired a new stake in DBV Technologies in the 4th quarter valued at about $10,064,000. Vestal Point Capital LP purchased a new position in DBV Technologies in the 4th quarter worth approximately $5,751,000. Squadron Capital Management LLC acquired a new position in shares of DBV Technologies during the 4th quarter worth approximately $4,601,000. Millennium Management LLC grew its position in shares of DBV Technologies by 89.7% in the fourth quarter. Millennium Management LLC now owns 640,885 shares of the company's stock valued at $12,286,000 after purchasing an additional 303,022 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in shares of DBV Technologies in the fourth quarter valued at approximately $479,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该公司的股票。Ikarian Capital LLC 在第四季度收购了 DBV Technologies 的新股份，价值约为 10,064,000 美元。Vestal Point Capital LP 在第四季度购买了 DBV Technologies 的新头寸，价值约为 5,751,000 美元。Squadron Capital Management LLC 在第四季度收购了 DBV Technologies 的股份，价值约为 4,601,000 美元。Millennium Management LLC 在第四季度将其在 DBV Technologies 的股份增加了 89.7%。Millennium Management LLC 现在拥有 640,885 股该公司的股票，价值为 12,286,000 美元，此前在上个季度又购买了 303,022 股。最后，Engineers Gate Manager LP 在第四季度购买了 DBV Technologies 的新股份，价值约为 479,000 美元。目前 71.74% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a research note on Wednesday, December 17th. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a research report on Thursday, December 18th. Citigroup reaffirmed an &#34;outperform&#34; rating on shares of DBV Technologies in a report on Wednesday, December 17th. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of DBV Technologies in a research report on Monday, December 29th. Finally, Guggenheim reissued a &#34;buy&#34; rating and set a $51.00 target price on shares of DBV Technologies in a research note on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $38.65.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对该股票发布了报告。Cantor Fitzgerald 在 12 月 17 日星期三的研究报告中将 DBV Technologies 的目标价设定为$48.00。HC Wainwright 在 12 月 18 日星期四的研究报告中将 DBV Technologies 的目标价设定为$40.00。花旗集团在 12 月 17 日星期三的报告中重申了对 DBV Technologies 的 “跑赢大盘” 评级。Weiss Ratings 在 12 月 29 日星期一的研究报告中重申了对 DBV Technologies 的 “卖出（e+）” 评级。最后，Guggenheim 在 3 月 27 日星期五的研究报告中重新发布了 “买入” 评级，并将 DBV Technologies 的目标价设定为$51.00。两位研究分析师对该股票给予了强烈买入评级，四位给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为$38.65。</p>
</div><p><strong>Check Out Our Latest Research Report on DBVT</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 DBVT 的最新研究报告</strong></p>
</div><h2>About DBV Technologies</h2>
<div class="lb-trans"><h2>关于 DBV Technologies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.</p>
<div class="lb-trans"><p>DBV Technologies SA 是一家临床阶段的生物制药公司，专注于开发过敏性疾病的免疫疗法。该公司专注于皮肤免疫疗法，利用其专有的 Viaskin 平台通过完整的皮肤传递生物活性化合物，无需针头或注射。通过这种方法，DBV 旨在调节患者对特定过敏原的免疫反应，提供一种潜在更安全和更便捷的替代传统疗法的选择。</p>
</div><p>The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 Viaskin Peanut 旨在治疗儿童和青少年的花生过敏。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than DBV Technologies</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 DBV Technologies 更好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REJWVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DBVT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DBV Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 DBV Technologies 吗？</h2>
</div><p>Before you consider DBV Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 DBV Technologies 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 DBV Technologies 并不在名单上。</p>
</div><p>While DBV Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 DBV Technologies 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

DBV Technologies (DBVT) 预计将在周五发布季度财报